Appl. No. 10/760,064
Amdt. dated October 24, 2006
Office Action dated April 25, 2006

PATENT

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

The list of currently pending claims is presented below.

1.   (Currently amended) A method of modulating an Edg-3 receptor mediated biological activity comprising contacting a cell expressing the Edg-3 receptor with an amount of ~~an~~ a modulator of the Edg-3 receptor sufficient to modulate the Edg-3 receptor mediated biological activity wherein the modulator is a compound of ~~the structural formula~~ Formula (I):

$$R_3 \diagup \overset{\overset{R_1}{\underset{|}{N}}}{} \diagdown R_2$$

(I)

or a pharmaceutically ~~available~~ acceptable solvate or hydrate thereof, wherein~~;~~

each ~~of~~ R_1, R_2 and R_3 is a member independently selected from the group consisting of

-H, -halo, $-NO_2$, -CN, $-C(R_5)_3$, $-(CH_2)_mOH$, $-N(R_5)(R_5)$, $-O(CH_2)_mR_5$, $-C(O)R_5$,

$-C(O)NR_5R_5$, $-C(O)NH(CH_2)_m(R_5)$, $-OCF_3$, -benzyl, -phenyl, $-CO_2CH(R_5)(R_5)$,

$-(C_1-C_{10})alkyl$, $-(C_2-C_{10})alkenyl$, $-(C_2-C_{10})alkynyl$, $-(C_3-C_{10})cycloalkyl$,

$-(C_8-C_{14})bicycloalkyl$, $-(C_5-C_{10})cycloalkenyl$, $-(C_5)heteroaryl$, $-(C_6)heteroaryl$,

$-(C_5-C_{10})heteroaryl$, -naphthyl, $-(C_3-C_{10})heterocycle$, $-CO_2(CH_2)_mR_5$, -N(OH)aryl,

$-NHC(O)R_5$, $-NHC(O)OR_5$, $-NHC(O)NHR_5$, ~~heterocylcoalkyl~~ heterocycloalkyl,

$-C(S)N(R_5)(R_5)$, $-(C_1-C_{10})alkylNHC(O)(CH_2)_mR_5$, $-(C_1-C_{10})alkylNR_5R_5$

$-OC(O)(CH_2)mCHR_5R_5$, $-CO_2(CH_2)_mCHR_5R_5$, $-OC(O)OR_5$, $-SR_5$, $-S(O)R_5$,

$-S(O)_2R_5$, $-S(O)_2NHR_5$, ~~or~~ and

1-SF/7385164.1

20

21 ~~R_3 is H, $C(R_5)_3$, $(CH_2)_mOH$, $C(O)R_5$, $C(O)NR_5R_5$, $C(O)NH(CH_2)m(R_5)$,~~

22 ~~benzyl, $CO_2CH(R_5)(R_5)$, (C_1-C_{10})alkyl, (C_2-C_{10})alkenyl,~~

23 ~~(C_2-C_{10})alkynyl, (C_3-C_{10})cycloalkyl, (C_8-C_{14})bicycloalkyl,~~

24 ~~(C_5-C_{10})cycloalkenyl, (C_5)heteroaryl, (C_6)heteroaryl,~~

25 ~~(C_5-C_{10})heteroaryl, naphthyl, (C_3-C_{10})heterocycle, $CO_2(CH_2)_mR_5$,~~

26 ~~$N(OH)$aryl, $NHC(O)R_5$, $NHC(O)OR_5$, $NHC(O)NHR_5$, $N=C(aryl)$,~~

27 ~~heterocycloalkyl, (C_1-C_{10})alkylNHC(O)$(CH_2)_mR_5$, (C_1-C_{10})alkylNR_5R_5,~~

28 ~~$OC(O)(CH_2)_mCHR_5R_5$, $CO_2(CH_2)_mCHR_5R_5$, $OC(O)OR_5$, SR_5, $S(O)R_5$,~~

29 ~~$S(O)_2R_5$, $S(O)_2NHR_5$, or~~

30

31 wherein~~;~~

32 each R_5 and R_6 is <u>a member</u> independently <u>selected from group consisting of</u> -H,

33 -halo, -NO_2, -CN, -OH, -CO_2H, -$N(C_1-C_{10})$alkyl(C_1-C_{10})alkyl,

34 -$O(C_1-C_{10})$alkyl, -$C(O)(C_1-C_{10})$alkyl, -$C(O)NH(CH_2)_m(C_1-C_{10})$alkyl,

35 -OCF_3, -benzyl, -$CO_2(CH_2)_mCH((C_1-C_{10})$alkyl$(C_1-C_{10})$alkyl),

36 -$CO_2(C_1-C_{10})$alkyl, -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl,

37 -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_5-C_{10})cycloalkenyl,

38 -(C_5)heteroaryl, -(C_6)heteroaryl, -phenyl, naphthyl, -(C_3-C_{10})heterocycle,

39 -$CO_2(CH_2)_m(C_1-C_{10})$alkyl, -$CO_2(CH_2)_mH$, -$NHC(O)(C_1-C_{10})$alkyl,

40 -$NHC(O)NH(C_1-C_{10})$alkyl, -$NH(aryl)$, -$N=C(aryl)$,

41 -$OC(O)O(C_1-C_{10})$alkyl, ~~or~~ <u>and</u> -SO_2NH_2;

42 X is <u>selected from</u> O, S, ~~or~~ <u>and</u> $N(R_5)$;

1-SF/7385164.1

Appl. No. 10/760,064
Amdt. dated October 24, 2006
Office Action dated April 25, 2006

PATENT

43   R_1, R_2 or R_3 taken in combination can form one or more substituted or unsubstituted 5 or

44   6 membered cyclic or heterocyclic rings or a 6-membered aromatic ring;

45   two R_6 groups on adjacent carbon atoms can together form a 5 or 6 membered cyclic or

46   heterocyclic ring or a 6-membered aromatic ring;

47   each m is independently an integer ranging from 0 to 8; and

48   each p is independently an integer ranging from 0 to 5.

1   **2.**   (Currently amended) A method of modulating an ~~Edg-2~~ Edg-3 receptor mediated

2   biological activity in a subject comprising administering to the subject a therapeutically effective

3   amount of a modulator of the ~~Edg-2~~ Edg-3 receptor wherein the modulator is a compound of ~~the~~

4   ~~structural formula~~ Formula (II):

5   (II)

6   or a pharmaceutically ~~available~~ acceptable solvate or hydrate thereof, wherein;

7   each ~~of~~ R_1, R_2, R_3, R_4, R_7 and R_8 is a member independently selected from the group

8   consisting of -H, -halo, $-NO_2$, -CN, $-C(R_5)_3$, $-(CH_2)_mOH$, $-N(R_5)(R_5)$,

9                 $-O(CH_2)_mR_5$, $-C(O)R_5$, $-C(O)NR_5R_5$, $-C(O)NH(CH_2)_m(R_5)$, $-OCF_3$, -benzyl,

10               $-CO_2CH(R_5)(R_5)$, $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl,

11               $-(C_3-C_{10})$cycloalkyl, $-(C_8-C_{14})$bicycloalkyl, $-(C_5-C_{10})$cycloalkenyl,

12               $-(C_5)$heteroaryl, $-(C_6)$heteroaryl, $-(C_5-C_{10})$heteroaryl, -naphthyl,

13               $-(C_3-C_{10})$heterocycle, $-CO_2(CH_2)_mR_5$, -N(OH)aryl, $-NHC(O)R_5$, $-NHC(O)OR_5$,

14               $-NHC(O)NHR_5$, ~~-heterocyleoalkyl-~~ -heterocycloalkyl, $-C(S)N(R_5)(R_5)$,

15               $-(C_1-C_{10})$alkylNHC(O)$(CH_2)_mR_5$, $-(C_1-C_{10})$alkylNR_5R_5, $-OC(O)(CH_2)mCHR_5R_5$,

16               $-CO_2(CH_2)_mCHR_5R_5$, $OC(O)OR_5$, $-SR_5$, $-S(O)R_5$, $-S(O)_2R_5$, $-S(O)_2NHR_5$, ~~or~~ and

17

Appl. No. 10/760,064
Amdt. dated October 24, 2006
Office Action dated April 25, 2006

PATENT

18
19
20 ~~R_3 is H, $-C(R_5)_3$, $-(CH_2)_mOH$, $-C(O)R_5$, $-C(O)NR_5R_5$, $-C(O)NH(CH_2)_m(R_5)$,~~

21 ~~$-$benzyl, $-CO_2CH(R_5)(R_5)$, $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl,~~

22 ~~$-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, $-(C_9-C_{14})$bicycloalkyl,~~

23 ~~$-(C_5-C_{10})$cycloalkenyl, $-(C_5)$heteroaryl, $-(C_6)$heteroaryl,~~

24 ~~$-(C_5-C_{10})$heteroaryl, naphthyl, $-(C_3-C_{10})$heterocycle, $-CO_2(CH_2)_mR_5$,~~

25 ~~$-N(OH)$aryl, $-NHC(O)R_5$, $-NHC(O)OR_5$, $-NHC(O)NHR_5$, $-N=C(aryl)$,~~

26 ~~$-$heterocyleoalkyl, $-(C_1-C_{10})$alkyl$NHC(O)(CH_2)_mR_5$, $-(C_1-C_{10})$alkylNR_5R_5,~~

27 ~~$-OC(O)(CH_2)_mCHR_5R_5$, $-CO_2(CH_2)$.CHR_5R_5, $-OC(O)OR_5$, $-SR_5$, $-S(O)R_5$,~~

28 ~~$-S(O)_2R_5$, $-S(O)_2NHR_5$, or~~

29

30 wherein~~;~~

31 each R_5 and R_6 is <u>a member</u> independently <u>selected from the group consisting of</u>

32 $-H$, $-halo$, $-NO_2$, $-CN$, $-OH$, $-CO_2H$, $-N(C_1-C_{10})$alkyl(C_1-C_{10})alkyl,

33 $-O(C_1-C_{10})$alkyl, $-C(O)(C_1-C_{10})$alkyl, $-C(O)NH(CH_2)_m(C_1-C_{10})$alkyl,

34 $-OCF_3$, $-$benzyl, $-CO_2(CH_2)_mCH((C_1-C_{10})$alkyl$(C_1-C_{10})$alkyl),

35 $-CO_2(C_1-C_{10})$alkyl, $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl,

36 $-(C_3-C_{10})$cycloalkyl, $-(C_8-C_{14})$bicycloalkyl, $-(C_5-C_{10})$cycloalkenyl,

37 $-(C_5)$heteroaryl, $-(C_6)$heteroaryl, $-$phenyl, naphthyl, $-(C_3-C_{10})$heterocycle,

38 $-CO_2(CH_2)_m(C_1-C_{10})$alkyl, $-CO_2(CH_2)_mH$, $-NHC(O)(C_1-C_{10})$alkyl,

39 $-NHC(O)NH(C_1-C_{10})$alkyl, $-NH(aryl)$, $-N=C(aryl)$,

40 $-OC(O)O(C_1-C_{10})$alkyl, ~~or~~ <u>and</u> $-SO_2NH_2$;

41 X is <u>selected from</u> O, S, ~~or~~ <u>and</u> $N(R_5)$;

1-SF/7385164.1

Appl. No. 10/760,064
Amdt. dated October 24, 2006
Office Action dated April 25, 2006

PATENT

42   R_1 and R_2, R_2 and R_3, R_3 and R_4, R_4 and R_7, or R_7 and R_8 taken in combination can form

43   one or more substituted or unsubstituted 5 or 6 membered cyclic or heterocyclic

44   rings or a 6-membered aromatic ring;

45   two R_6 groups on adjacent carbon atoms can together form a 5 or 6 membered cyclic or

46   heterocyclic ring or a 6-membered aromatic ring;

47   each m is independently an integer ranging from 0 to 8; and

48   each p is independently an integer ranging from 0 to 5.

1   **3.**   (Original) The method of Claim **1** or **2**, wherein the modulator is an agonist.

1   **4.**   (Original) The method of Claim **1** or **2**, wherein the modulator is an antagonist.

1   **5.**   (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits

2   at least about 200 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to other Edg receptors.

1   **6.**   (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits

2   at least about 40 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to other Edg receptors.

1   **7.**   (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits

2   at least about 12 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to other Edg receptors.

1   **8.**   (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits

2   at least about 5 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to other Edg receptors.

1   **9.**   (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits

2   at least about 20 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to other Edg receptors.

1   **10.**   (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits

2   at least about 200 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to Edg-4 and Edg-7

3   receptors.

1   **11.**   (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits

2   at least about 40 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to Edg-4 and Edg-7

1-SF/7385164.1

Appl. No. 10/760,064
Amdt. dated October 24, 2006
Office Action dated April 25, 2006

PATENT

3   receptors.

1   **12.**   (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits

2   at least about 12 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to Edg-4 and Edg-7

3   receptors.

1   **13.**   (Currently amended) The method of Claim **1** or **2**, wherein the modulator exhibits

2   at least about 5 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to Edg-4 and Edg-7 receptors.

1   **14.**   (Original) The method of Claim **1** or **2**, wherein the biological activity is cell

2   proliferation.

1   **15.**   (Currently amended) The method of Claim **14**, wherein the modulator exhibits at

2   least about 200 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to other Edg receptors.

1   **16.**   (Currently amended) The method of Claim **14**, wherein the modulator exhibits at

2   least about 5 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to other Edg receptors.

1   **17.**   (Currently amended) The method of Claim **14**, wherein the modulator exhibits at

2   least about 200 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to Edg-4 and Edg-7 receptors.

1   **18.**   (Currently amended) The method of Claim **14**, wherein the modulator exhibits at

2   least about 5 fold inhibitory selectivity for ~~Edg-2~~ Edg-3 relative to Edg-4 and Edg-7 receptors.

1   **19.**   (Currently amended) The method of Claim **14**, wherein cell proliferation leads to

2   cancer selected from the group consisting of ovarian cancer, peritoneal cancer, endometrial

3   cancer, cervical cancer, breast cancer, colon cancer ~~or~~ and ~~prostrate~~ prostate cancer.

1   **20.**   (Original) The method of Claim **14**, wherein cell proliferation is stimulated by

2   LPA.

1   **21.**   (Currently amended) The method of Claim **1** or **2**, wherein the biological activity

2   is selected from the group consisting of calcium mobilization, VEGF synthesis, IL-8 synthesis,

1-SF/7385164.1

Appl. No. 10/760,064
Amdt. dated October 24, 2006
Office Action dated April 25, 2006

PATENT

3 platelet activation, cell migration, phosphoinositide hydrolysis, inhibition of cAMP formation,

4 actin polymerization, apoptosis, angiogenesis, inhibition of wound healing, inflammation, cancer

5 invasiveness, supressing autoimmune responses, ~~or~~ <u>and</u> atherogenesis.

1 **22.**   (Currently amended) The method of Claim **1** or **2** wherein the modulator binds to

2 the ~~Edg-2~~ <u>Edg-3</u> receptor with a binding constant of at least about 10 ~~nm~~ <u>nM</u>.

1 **23.**   (Currently amended) The method of Claim **1** or **2** wherein the modulator binds to

2 the ~~Edg-2~~ <u>Edg-3</u> receptor with a binding constant between about <u>100 fM and</u> 1 μM<u>.</u> ~~and 100 fM.~~


1 **24.**   (Original) The method of Claim **1** or **2**, wherein the modulator is a nucleic acid,

2 protein or carbohydrate.

1 **25.**   (Original) The method of Claim **1** or **2**, wherein the modulator is an organic

2 molecule of molecular weight of less than 750 daltons.

1 **26.**   (Currently amended) The method of Claim **1**, wherein the cell is <u>selected from the</u>

2 <u>group consisting of</u> a hepatoma cell, an ovarian cell, an epithelial cell, a fibroblast cell, a

3 neuronal cell, a carcinoma cell, a pheochromocytoma cell, a myoblast cell, a platelet cell ~~or~~ <u>and</u> a

4 fibrosarcoma cell.

1 **27.**   (Currently amended) The method of Claim **21**, wherein the cell is <u>selected from</u>

2 <u>the group consisting of</u> OV202 human ovarian cell, a HTC rat hepatoma cell, a CAOV-3 human

3 ovarian cancer cell, MDA-MB-453 breast cancer cell, MDA-MB-231 breast cancer cell, HUVEC

4 cells A431 human epitheloid carcinoma cell ~~or~~ <u>and</u> a HT-1080 human fibrosarcoma cell.

1 **28.**   (Currently amended) The method of Claim ~~25~~ <u>1 or 2</u> wherein the modulator has

2 the <u>a</u> ~~following structural~~ formula <u>selected from</u>:

3

1-SF/7385164.1

Appl. No. 10/760,064
Amdt. dated October 24, 2006
Office Action dated April 25, 2006

PATENT

113

115

4
5
6
7

117   ; and

119

8
9
10

1   **29.**   (Currently amended) A method for treating or preventing <u>a disease or condition</u>

2   <u>selected from the group consisting of</u> cancers, acute lung diseases, acute inflammatory

3   exacerbation of chronic lung diseases, surface epithelial cell injury, ~~or~~ <u>and</u> cardiovascular

4   diseases in a patient <u>in need of said treatment or said prevention, said method</u> comprising

5   administering to ~~a~~ <u>said</u> patient ~~in need of such treatment or prevention~~ a therapeutically effective

6   amount of a compound of ~~structural formula~~ <u>Formulae</u> (I) or (II).

1   **30.**   (Currently amended) A method for treating or preventing <u>a disease or condition</u>

2   <u>selected from the group consisting of</u> ovarian cancer, peritoneal cancer, endometrial cancer;

3   cervical cancer, breast cancer, colorectal cancer, uterine cancer, stomach cancer, small intestine

4   cancer, thyroid cancer, lung cancer, kidney cancer, pancreas cancer, ~~prostrate~~ <u>prostate</u> cancer,

5   adult respiratory distress syndrome (ARDS), asthma, transcorneal freezing, cutaneous burns,

6   ischemia ~~or~~ <u>and</u> ~~arthesclerosis~~ <u>atherosclerosis</u> in a patient <u>in need of said treatment or said</u>

7   <u>prevention, said method</u> comprising administering to ~~a~~ <u>said</u> patient ~~in need of such treatment or~~

8   ~~prevention~~ a therapeutically effective amount of a compound of ~~structural formula~~ <u>Formulae</u> (I)

Appl. No. 10/760,064
Amdt. dated October 24, 2006
Office Action dated April 25, 2006

PATENT

9   or (II).

1   **31.**   (Currently amended) A method for treating or preventing <u>a disease or condition</u>

2   <u>selected from the group consisting of</u> cancers, acute lung diseases, acute inflammatory

3   ·exacerbation of chronic lung diseases, surface epithelial cell injury, ~~or~~ <u>and</u> cardiovascular

4   diseases in a patient <u>in need of said treatment or said prevention, said method</u> comprising

5   administering to ~~a~~ <u>said</u> patient ~~in need of such treatment or prevention~~ a therapeutically effective

6   amount of a compound of ~~structural formula~~ <u>Formulae</u> (I) or (II) and one or more agonists or

7   antagonists of an ~~Edg-2~~ <u>Edg-3</u> receptor.

1   **32.**   (Currently amended) A method for treating or preventing <u>a disease or condition</u>

2   <u>selected from the group consisting of</u> cancers, acute lung diseases, acute inflammatory

3   exacerbation of chronic lung diseases, surface epithelial cell injury, ~~or~~ <u>and</u> cardiovascular

4   diseases in a patient <u>in need of said treatment or said prevention, said method</u> comprising

5   administering to ~~a~~ <u>said</u> patient ~~in need of such treatment or prevention~~ a therapeutically effective

6   amount of a compound of ~~structural formula~~ <u>Formulae</u> (I) or (II) and one or more drugs useful in

7   treating or preventing cancers, acute lung diseases, acute inflammatory exacerbation of chronic

8   lung diseases, surface epithelial cell injury, or cardiovascular diseases.

1   **33.**   (New) A method of treating cardiovascular disease in a patient comprising:

2   ·administering to the patient a therapeutically effective amount of a modulator of an Edg-3

3   receptor wherein the receptor is a compound of Formula (III):

$$R_3 \diagdown \underset{\underset{H}{|}}{N} \diagdown \underset{\underset{\underset{O}{\|}}{}}{C} - CH_3$$

(III)

4

5   or a pharmaceutically acceptable solvate or hydrate thereof, wherein

Appl. No. 10/760,064
Amdt. dated October 24, 2006
Office Action dated April 25, 2006

PATENT

6   R_3 is independently a member selected from the group consisting of -H, -halo, -NO$_2$,

7   -CN, -C(R$_5$)$_3$, -(CH$_2$)$_m$OH, -N(R$_5$)(R$_5$), -O(CH$_2$)$_m$R$_5$, -C(O)R$_5$, -C(O)NR$_5$R$_5$,

8   -C(O)NH(CH$_2$)$_m$(R$_5$), -OCF$_3$, -benzyl,- -phenyl, -CO$_2$CH(R$_5$)(R$_5$), -(C$_1$-C$_{10}$)alkyl,

9   -(C$_2$-C$_{10}$)alkenyl, -(C$_2$-C$_{10}$)alkynyl, -(C$_3$-C$_{10}$)cycloalkyl, -(C$_8$-C$_{14}$)bicycloalkyl,

10   -(C$_5$-C$_{10}$)cycloalkenyl, -(C$_5$)heteroaryl, -(C$_6$)heteroaryl, -(C$_5$-C$_{10}$)heteroaryl,

11   -naphthyl, -(C$_3$-C$_{10}$)heterocycle, -CO$_2$(CH$_2$)$_m$R$_5$, -N(OH)aryl, -NHC(O)R$_5$,

12   -NHC(O)OR$_5$, -NHC(O)NHR$_5$, -heterocycloalkyl, -C(S)N(R$_5$)(R$_5$),

13   -(C$_1$-C$_{10}$)alkylNHC(O)(CH$_2$)$_m$R$_5$, -(C$_1$-C$_{10}$)alkylNR$_5$R$_5$, -OC(O)(CH$_2$)mCHR$_5$R$_5$,

14   -CO$_2$(CH$_2$)$_m$CHR$_5$R$_5$, OC(O)OR$_5$, -SR$_5$, -S(O)R$_5$, -S(O)$_2$R$_5$, -S(O)$_2$NHR$_5$, and

15

16
17

18   wherein

19   each R$_5$ and R$_6$ is a member independently selected from the group consisting of

20   -H, -halo, -NO$_2$, -CN, -OH, -CO$_2$H, -N(C$_1$-C$_{10}$)alkyl, (C$_1$-C$_{10}$)alkyl,

21   -O(C$_1$-C$_{10}$)alkyl, -C(O)(C$_1$-C$_{10}$)alkyl, -C(O)NH(CH$_2$)$_m$(C$_1$-C$_{10}$)alkyl,

22   -OCF$_3$, -benzyl, -phenyl, -CO$_2$(CH$_2$)$_m$CH((C$_1$-C$_{10}$)alkyl(C$_1$-C$_{10}$)alkyl),

23   -CO$_2$(C$_1$-C$_{10}$)alkyl, -(C$_1$-C$_{10}$)alkyl, -(C$_2$-C$_{10}$)alkenyl, -(C$_2$-C$_{10}$)alkynyl,

24   -(C$_3$-C$_{10}$)cycloalkyl, -(C$_8$-C$_{14}$)bicycloalkyl, -(C$_5$-C$_{10}$)cycloalkenyl,

25   -(C$_5$)heteroaryl, -(C$_6$)heteroaryl, -phenyl, naphthyl, -(C$_3$-C$_{10}$)heterocycle,

26   -CO$_2$(CH$_2$)$_m$(C$_1$-C$_{10}$)alkyl, -CO$_2$(CH$_2$)$_m$H, -NHC(O)(C$_1$-C$_{10}$)alkyl,

27   -NHC(O)NH(C$_1$-C$_{10}$)alkyl, -NH(aryl), -N=C(aryl),

28   -OC(O)O(C$_1$-C$_{10}$)alkyl, and -SO$_2$NH$_2$;

29   each m is independently an integer ranging from 0 to 8; and

30   each p is independently an integer ranging from 0 to 5.

1   **34.**   (New) The method of claim **33**, wherein R$_3$ is a phenyl group.

Appl. No. 10/760,064
Amdt. dated October 24, 2006
Office Action dated April 25, 2006

PATENT

1   **35.**   (New) The method of claim **34**, wherein said phenyl group is substituted.

1   **36.**   (New) The method of claim **35**, wherein said compound is

117

2

1   **37.**   (New) The method of claim **33**, wherein said cardiovascular disease is selected

2 from the group consisting of ischemia and atherosclerosis.

1   **38.**   (New) A method of treating cardiovascular disease in a patient comprising:

2   administering to the patient a therapeutically effective amount of a modulator of an Edg-3

3   receptor wherein the receptor is a compound of Formula (IV):

(IV)

4

5 or a pharmaceutically acceptable solvate or hydrate thereof, wherein

6   each R_2 is a member independently selected from the group consisting of -H, -halo, -NO$_2$,

7   -CN, -C(R$_5$)$_3$, -(CH$_2$)$_m$OH, -N(R$_5$)(R$_5$), -O(CH$_2$)$_m$R$_5$, -C(O)R$_5$, -C(O)NR$_5$R$_5$,

Appl. No. 10/760,064
Amdt. dated October 24, 2006
Office Action dated April 25, 2006

PATENT

8 -C(O)NH(CH$_2$)$_m$(R$_5$), -OCF$_3$, -benzyl, -CO$_2$CH(R$_5$)(R$_5$), -(C$_1$-C$_{10}$)alkyl,

9 -(C$_2$-C$_{10}$)alkenyl, -(C$_2$-C$_{10}$)alkynyl, -(C$_3$-C$_{10}$)cycloalkyl, -(C$_8$-C$_{14}$)bicycloalkyl,

10 -(C$_5$-C$_{10}$)cycloalkenyl, -(C$_5$)heteroaryl, -(C$_6$)heteroaryl, -(C$_5$-C$_{10}$)heteroaryl,

11 -naphthyl, -(C$_3$-C$_{10}$)heterocycle, -CO$_2$(CH$_2$)$_m$R$_5$, -N(OH)aryl, -NHC(O)R$_5$,

12 -NHC(O)OR$_5$, -NHC(O)NHR$_5$, -heterocylcoalkyl, -C(S)N(R$_5$)(R$_5$),

13 -(C$_1$-C$_{10}$)alkylNHC(O)(CH$_2$)$_m$R$_5$, -(C$_1$-C$_{10}$)alkylNR$_5$R$_5$, -OC(O)(CH$_2$)mCHR$_5$R$_5$,

14 -CO$_2$(CH$_2$).CHR$_5$R$_5$, OC(O)OR$_5$, -SR$_5$, -S(O)R$_5$, -S(O)$_2$R$_5$, -S(O)$_2$NHR$_5$, and

15

16
17

18 wherein

19 each R$_5$ and R$_6$ is a member independently selected from the group consisting of

20 -H, -halo, -NO$_2$, -CN, -OH, -CO$_2$H, -N(C$_1$-C$_{10}$)alkyl, (C$_1$-C$_{10}$)alkyl,

21 -O(C$_1$-C$_{10}$)alkyl, -C(O)(C$_1$-C$_{10}$)alkyl, -C(O)NH(CH$_2$)m(C$_1$-C$_{10}$)alkyl,

22 -OCF$_3$, -benzyl, -CO$_2$(CH$_2$)$_m$CH((C$_1$-C$_{10}$)alkyl(C$_1$-C$_{10}$)alkyl),

23 -CO$_2$(C$_1$-C$_{10}$)alkyl, -(C$_1$-C$_{10}$)alkyl, -(C$_2$-C$_{10}$)alkenyl, -(C$_2$-C$_{10}$)alkynyl,

24 -(C$_3$-C$_{10}$)cycloalkyl, -(C$_8$-C$_{14}$)bicycloalkyl, -(C$_5$-C$_{10}$)cycloalkenyl,

25 -(C$_5$)heteroaryl, -(C$_6$)heteroaryl, -phenyl, naphthyl, -(C$_3$-C$_{10}$)heterocycle,

26 -CO$_2$(CH$_2$)$_m$(C$_1$-C$_{10}$)alkyl, -CO$_2$(CH$_2$)$_m$H, -NHC(O)(C$_1$-C$_{10}$)alkyl,

27 -NHC(O)NH(C$_1$-C$_{10}$)alkyl, -NH(aryl), -N=C(aryl),

28 -OC(O)O(C$_1$-C$_{10}$)alkyl, and -SO$_2$NH$_2$;

29 each m is independently an integer ranging from 0 to 8; and

30 each p is independently an integer ranging from 0 to 5.

1 **39.** (New) The method of claim **38**, wherein R$_2$ is -C(O)R$_5$.

1 **40.** (New) The method of claim **39**, wherein R$_5$ is a (C$_1$-C$_{10}$)alkyl group.

1 **41.** (New) The method of claim **40**, wherein said (C$_1$-C$_{10}$)alkyl is a methyl group.

Appl. No. 10/760,064
Amdt. dated October 24, 2006
Office Action dated April 25, 2006

PATENT

1   **42.**   (New) The method of claim **38**, wherein said cardiovascular disease is selected

2   from the group consisting of ischemia and atherosclerosis.